v3.26.1
Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Conversion of Legacy Blaize convertible notes
Net exercise of Legacy Blaize warrants
Common Stock Subject to Possible Redemption
Common Stock
Common Stock
Conversion of Legacy Blaize convertible notes
Common Stock
Net exercise of Legacy Blaize warrants
Additional Paid-in Capital
Additional Paid-in Capital
Conversion of Legacy Blaize convertible notes
Additional Paid-in Capital
Net exercise of Legacy Blaize warrants
Accumulated Other Comprehensive Income
Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2024       0                
Beginning balance at Dec. 31, 2024       $ 0                
Increase (Decrease) in Temporary Equity [Roll Forward]                        
Merger and PIPE financing (in shares)       2,854,242                
Merger and PIPE financing       $ 33,061                
Ending balance at Mar. 31, 2025       $ 33,061                
Ending balance (in shares) at Mar. 31, 2025       2,854,242                
Beginning balance (in shares) at Dec. 31, 2024         48,376,052              
Beginning balance at Dec. 31, 2024 $ (110,463)       $ 5     $ 318,783     $ 0 $ (429,251)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Conversion of Legacy Blaize convertible notes and Net exercise of Legacy Blaize warrants (in shares)           31,433,259 7,505,657          
Conversion of Legacy Blaize convertible notes and Net exercise of Legacy Blaize warrants   $ 314,334 $ 75,057     $ 3 $ 1   $ 314,331 $ 75,056    
Merger and PIPE financing (in shares)         11,408,957              
Merger and PIPE financing (126,164)       $ 1     (126,165)        
Payment on shareholder note receivable 200             200        
Issuance of common stock to advisors (in shares)         94,949              
Issuance of common stock to advisors 300             300        
Issuance of common stock warrants to advisor 167             167        
Stock-based compensation 11,040             11,040        
Other comprehensive income 0                      
Net loss (147,761)                     (147,761)
Ending balance (in shares) at Mar. 31, 2025         98,818,874              
Ending balance at Mar. 31, 2025 $ 16,710       $ 10     593,712     0 (577,012)
Beginning balance (in shares) at Dec. 31, 2025 122,043,966       122,043,966              
Beginning balance at Dec. 31, 2025 $ 39,000       $ 12     675,143     0 (636,155)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Exercise of stock options (in shares) 49,202       49,202              
Exercise of stock options $ 25             25        
Releases of restricted stock units (in shares)         653,589              
Stock-based compensation 8,948             8,948        
Other comprehensive income 125                   125  
Net loss $ (22,653)                     (22,653)
Ending balance (in shares) at Mar. 31, 2026 122,746,757       122,746,757              
Ending balance at Mar. 31, 2026 $ 25,445       $ 12     $ 684,116     $ 125 $ (658,808)